ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
October 20, 2021Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions... -
Eisai and Wren Therapeutics to collaborate for drug discovery for synucleinopathies
December 01, 2020This collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of α-synuclein misfolding and aggregation.
Pharma Sources Insight January 2025
